Aliskiren + Amlodipine + Placebo Aliskiren + Placebo Amlodipine
Phase 2Completed 0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
High Blood Pressure
Conditions
High Blood Pressure, Metabolic Syndrome, Insulin Resistance, Endothelial Dysfunction
Trial Timeline
Oct 1, 2007 → Jul 1, 2010
NCT ID
NCT00417170About Aliskiren + Amlodipine + Placebo Aliskiren + Placebo Amlodipine
Aliskiren + Amlodipine + Placebo Aliskiren + Placebo Amlodipine is a phase 2 stage product being developed by Novartis for High Blood Pressure. The current trial status is completed. This product is registered under clinical trial identifier NCT00417170. Target conditions include High Blood Pressure, Metabolic Syndrome, Insulin Resistance.
What happened to similar drugs?
6 of 20 similar drugs in High Blood Pressure were approved
Approved (6) Terminated (7) Active (9)
Hype Score Breakdown
Clinical
12
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00417170 | Phase 2 | Completed |
Competing Products
20 competing products in High Blood Pressure